Introduction: Assessment of disease status remains the fundamental basis in the management of gastro-entero-pancreatic neuro-endocrine tumors (GEPNETs). Circulating molecular information might be used as a liquid biopsy to predict its clinical course.
Aim(s): We assessed the ability of the NETest®, a multi-analyte liquid biopsy quantifying gene expression in blood, in comparison with chromogranin A (CgA), for the prediction of disease status at follow-up.
Materials and methods: 152 patients with GEPNETs were followed for a median of 33 [6-52] months. NETest® score and CgA were measured at baseline. Disease status at follow-up was defined by RECIST 1.1. Radiologists and laboratory staff were blinded for diagnostic results. Optimal scores were estimated using ROC-curve analysis: low tumor activity (NETest ≤ 33%; CgA <140 µg/L), intermediate tumor activity (NETest 34-79%) and high tumor activity (NETest ≥ 80%; CgA ≥ 140 µg/L).
Conference: 17th Annual ENETS Conference 2020 (2020)
Presenting Author: Mark van Treijen
van Treijen M
, van der Zee D
, Heeres B
, Staal F
, Vriens M R
, Saveur L
, Verbeek W
, Korse C
, Maas M
, Valk G D
, Tesselaar M
To read results and conclusion, please login ...
Further abstracts you may be interested in